Effects of 4-AP on Functional SCI Recovery
Key facts
- Who runs it
- Shirley Ryan AbilityLab
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 26 people enrolled
- Started
- 30 Jun 2022
- Ended
- 30 Jun 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dalfampridine
- Placebo drug
- STDP stimulation
- Exercise training
- Record updated
- 3 June 2026
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Male and females between ages 18-85 years
- SCI at least 4 weeks post injury
- Spinal Cord injury at or above L2
- ASIA A,B,C, or D, complete or incomplete
- Possess the following abilities
- The ability to perform a small visible contraction with dorsiflexion and hip flexor muscles
Who cannot take part
- Any debilitating disease prior to the SCI that caused exercise intolerance
- Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold (see appendix 2)
- Individuals with scalp shrapnel, cochlear implants, or aneurysm clips
- Individuals taking Bupropion, Dolutegravir, Lacosamide, Trilaciclib, or PR Interval prolonging drugs
- Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease
- Any history of renal impairment
- History of head injury or stroke
- Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication
- History of seizures or epilepsy
- If a women of child bearing age is unsure of the pregnancy, and does not want to take the pregnancy test Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida, MS, or herniated disk
- Premorbid, ongoing major depression or psychosis, altered cognitive status
- Pregnant females
- Metal plate in skull
Where in United States
- Shirley Ryan AbilityLabChicago, United States
About the trial
What the trial wants to find out
The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.
The 3 groups in the trial
- Dalfampridine (4-AP)+STDP+trainingExisting treatment, for comparison
The effects of the functional recovery of the lower-limb muscles will be determined after 10 sessions of 4-AP, STDP stimulation and training.
Treatment: Dalfampridine, STDP stimulation, and Exercise training
- Placebo+STDP+trainingPlacebo, for comparison
The effects of the functional recovery of the lower-limb muscles will be determined after 10 sessions of placebo drug, STDP stimulation and training.
Treatment: Placebo drug, STDP stimulation, and Exercise training
- Dalfampridine (4-AP)+STDP+training for extended sessionsTreatment being tested
The long-term effects of the functional recovery of the lower-limb muscles will be determined after 40 sessions of 4-AP, STDP stimulation and training.
Treatment: Dalfampridine, STDP stimulation, and Exercise training
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of 4-AP on Functional Recovery After Spinal Cord Injury
- Record updated
- 3 June 2026